ORIC vs. SLN, SIGA, ZYME, LBPH, AVTE, BCYC, LYEL, NUVB, YMAB, and ATXS
Should you be buying ORIC Pharmaceuticals stock or one of its competitors? The main competitors of ORIC Pharmaceuticals include Silence Therapeutics (SLN), SIGA Technologies (SIGA), Zymeworks (ZYME), Longboard Pharmaceuticals (LBPH), Aerovate Therapeutics (AVTE), Bicycle Therapeutics (BCYC), Lyell Immunopharma (LYEL), Nuvation Bio (NUVB), Y-mAbs Therapeutics (YMAB), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical preparations" industry.
ORIC Pharmaceuticals (NASDAQ:ORIC) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability and institutional ownership.
In the previous week, ORIC Pharmaceuticals and ORIC Pharmaceuticals both had 3 articles in the media. Silence Therapeutics' average media sentiment score of 0.52 beat ORIC Pharmaceuticals' score of 0.36 indicating that Silence Therapeutics is being referred to more favorably in the news media.
ORIC Pharmaceuticals received 25 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 68.97% of users gave Silence Therapeutics an outperform vote while only 65.22% of users gave ORIC Pharmaceuticals an outperform vote.
ORIC Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.
ORIC Pharmaceuticals has a net margin of 0.00% compared to Silence Therapeutics' net margin of -171.41%. ORIC Pharmaceuticals' return on equity of -42.71% beat Silence Therapeutics' return on equity.
ORIC Pharmaceuticals presently has a consensus target price of $19.80, indicating a potential upside of 108.20%. Silence Therapeutics has a consensus target price of $57.25, indicating a potential upside of 159.99%. Given Silence Therapeutics' higher possible upside, analysts plainly believe Silence Therapeutics is more favorable than ORIC Pharmaceuticals.
Silence Therapeutics has higher revenue and earnings than ORIC Pharmaceuticals. Silence Therapeutics is trading at a lower price-to-earnings ratio than ORIC Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
95.1% of ORIC Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 5.3% of ORIC Pharmaceuticals shares are owned by insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Silence Therapeutics beats ORIC Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get ORIC Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ORIC Pharmaceuticals Competitors List
Related Companies and Tools
